Hims & Hers Health, Inc. (NYSE:HIMS) Insider Michael Chi Sells 17,303 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 17,303 shares of Hims & Hers Health stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $27.97, for a total value of $483,964.91. Following the completion of the transaction, the insider now directly owns 193,601 shares in the company, valued at $5,415,019.97. This represents a 8.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Chi also recently made the following trade(s):

• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $26.00, for a total transaction of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $32.25, for a total transaction of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.
• On Friday, October 25th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.00, for a total value of $380,688.00.
• On Monday, October 21st, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.20, for a total transaction of $166,500.00.

Hims & Hers Health Trading Down 6.8 %

HIMS traded down $1.93 during trading on Friday, reaching $26.56. 8,844,547 shares of the company were exchanged, compared to its average volume of 10,054,175. Hims & Hers Health, Inc. has a 52 week low of $8.09 and a 52 week high of $35.02. The firm has a 50 day moving average of $26.29 and a 200 day moving average of $21.46. The stock has a market cap of $5.80 billion, a P/E ratio of 60.37 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.04) EPS. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. Renaissance Technologies LLC increased its position in Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after acquiring an additional 3,205,108 shares during the period. State Street Corp increased its holdings in shares of Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after purchasing an additional 206,078 shares during the period. Geode Capital Management LLC raised its stake in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after purchasing an additional 482,177 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after purchasing an additional 883,230 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Hims & Hers Health by 15.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after buying an additional 218,566 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Morgan Stanley started coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price target for the company. TD Cowen reiterated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Finally, Piper Sandler restated a “neutral” rating and issued a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.80.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.